![](/img/cover-not-exists.png)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Reich, Kristian, Papp, Kim A, Blauvelt, Andrew, Tyring, Stephen K, Sinclair, Rodney, Thaçi, Diamant, Nograles, Kristine, Mehta, Anish, Cichanowitz, Nicole, Li, Qing, Liu, Kenneth, La Rosa, Carmen, GreLanguage:
english
Journal:
The Lancet
DOI:
10.1016/S0140-6736(17)31279-5
Date:
June, 2017
File:
PDF, 740 KB
english, 2017